Novo Nordisk will reduce the U.S. list price of Wegovy by 50% to $675 per month effective January 1, 2027123.
Ozempic list price will drop by 35% to the same $675 per month, with Rybelsus also priced at $675123.
The cuts aim to improve affordability for patients with high-deductible plans and address competition in the GLP-1 market123.
Direct-to-patient and self-pay prices remain unchanged123.
Announcement made February 24, 2026, amid growing competition from Eli Lilly and others123.
Sources:
1. https://www.cbsnews.com/news/wegovy-ozempic-novo-nordisk-price-cut-january-2027/
2. https://www.foxbusiness.com/markets/novo-nordisk-slash-list-prices-ozempic-wegovy-up-50
3. https://www.prnewswire.com/news-releases/novo-nordisk-announces-significant-reduction-in-us-list-price-for-wegovy-ozempic-and-rybelsus-semaglutide-medicines-building-on-continued-efforts-to-expand-access-302695705.html